Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Victoria Brocklebank
Institution:
Newcastle University
Observed institutions:
Newcastle upon Tyne Hospitals NHS Foundation Trust,
University of Newcastle Australia,
Newcastle University
ORCID:
0000-0002-5217-0306
Observed ORCID:
0000-0002-5217-0306
OpenAlex ID:
A5034087559
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
2022
·
Sarah Dunn
, Victoria Brocklebank
, et al.
·
BMJ Open
·
13
PDF
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial
2025
·
Andrew Bryant
, Jan Lecouturier
, et al.
·
The Lancet Regional Health - Europe
·
12
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS
2025
·
Giovany Orozco-Leal
, Luke Vale
, et al.
·
Nephrology Dialysis Transplantation
·
5
PDF
A strategy of eculizumab treatment withdrawal with disease monitoring is cost-effective compared to lifelong treatment for eligible atypical haemolytic uraemic syndrome patients: an economic evaluation of the SETS aHUS trial
2025
·
Giovany Orozco-Leal
, Luke Vale
, et al.
·
medRxiv
·
1
PDF
The cost-effectiveness of replacing lifelong therapy of eculizumab with a strategy of disease monitoring for eligible atypical haemolytic uraemic syndrome (aHUS) patients: an economic evaluation of the SETS aHUS trial
2026
·
Giovany Orozco Leal
, Luke Vale
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
2025
·
Giovany Orozco Leal
, Luke Vale
, et al.
·
Value in Health
A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in Age-related Macular Degeneration
2022
·
TM Hallam
, Thomas Cox
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Functional characterisation of rare genetic variants in the N-terminus of complement factor H in aHUS, C3G and AMD
2021
·
Edwin Wong
, T Hallam
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Long-term outcomes and response to treatment in DGKE nephropathy
2020
·
Victoria Brocklebank
, G Kumar
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2
2019
·
Christopher Duncan
, Benjamin Thompson
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H–Related 3 Gene in Atypical Hemolytic Uremic Syndrome
2016
·
RC Challis
, GSR Araujo
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Characterisation of a C3 Mutation with Increased Resistance to Complement Regulation in an Individual with Recurrent C3GN in a Renel Transplant
2015
·
Edwin Wong
, Elizabeth Miller
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report
2015
·
Mustafa Sevinc
, Taner Basturk
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
Show more works
View as search
Works count:
13
Citation count:
31
H-index:
3
I10-index:
2
Year
Topic
Type